DOCSLIB.ORG

Drugs and Alcohol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drugs and Alcohol Drugs and Alcohol Do I have any problems with alcohol consumption? Introduction to alcohol The legal profession is both very stressful and usually well paid – Turning to drugs and alcohol when under a combination that leaves some legal professionals with both a reason and extreme stress or when suffering from varying degrees of depression and anxiety can become the means to drink heavily. The question is, do you have an alcohol problem? a way to escape. However, as this information Do you recognise yourself in any of these statements? will explain, taking drugs or drinking excessively • “I go out intending to have just one or two drinks, but then I just don’t can exacerbate the problems and make dealing with issues more challenging. seem to be able to stop.” Anecdotal evidence suggests substance use • “I’ve tried to cut down a couple of times. Once I even managed to go a disorders, characterised by dependence on whole week without drinking, just to prove to myself that I could do it.” alcohol or a drug, use of alcohol and drugs that can lead to problems at work, school or home • “Sometimes I feel a bit guilty about my drinking, or about the effect it has or to legal problems, and use of alcohol or drugs on other people. I know I’m letting people down and breaking promises.” at a level that is damaging to one’s health, are • “Other people sometimes comment on the amount I drink. It really higher in the legal industry compared to the normal population and in comparison to other irritates and annoys me. Why can’t they mind their own business?” professional industries. Research undertaken • “I really look forward to a drink. Sometimes I even count down the hours by the Brain and Mind Institute (Sydney 2009) until the next one, and if we’re going out and I’m worried there won’t be support the claim that mental health is indeed a enough alcohol when we get there I will have a couple of glasses before serious issue within the legal industry. Findings showed there were high levels of psychological we leave.” distress and risk of depression in law students • “I always feel better if I have a little drink fairly early in the day, just to and practicing solicitors and there was a general steady me.” reluctance to seek help for mental health issues. • “I drink more than some other people, but I know I’m not an alcoholic because I don’t drink spirits/only drink at weekends/I’m never blind drunk/I don’t drink as much as Joe Bloggs.” If just one of these statements rang true for you, then you could potentially have an alcohol problem and may require some professional help or assistance. Please note: Whilst this information is about alcohol, addiction to any drug or substance follows similar patterns and requires similar treatment. POWER OF ASSOCIATION INFORMATION AND PRACTICE RESOURCES POWER OF ASSOCIATION INFORMATION AND PRACTICE RESOURCES POWER OF ASSOCIATION Health & Wellbeing – Drugs and Alcohol Consumption rates and standard drinks What is a standard drink? The Brain and Mind Research Institute at the University of Sydney recently undertook Can/Stubbi low-strength beer 0.8 standard drink a comprehensive study where participants Can/Stubbi mid-strength beer 1 standard drink were asked to report on what they saw to be the most typical characteristics of a Can/Stubbi full-strength beer 1.4 standard drinks person with depression. Results showed 100ml wine (13.5% alcohol) 1 standard drink that 49.5 per cent of the 2,414 participants 30ml nip spirits 1 standard drink suggested dependence on alcohol, drugs or sedatives were typical behaviours exhibited Can spirits (approx 5% alcohol) 1.2 to 1.7 standard drinks by students, solicitors and barristers. Can spirits (approx 7% alcohol) 1.6 to 2.4 standard drinks Alcohol-related deaths and Source: www.nhmrc.gov.au/publications/synopses/_files/ds10-alcoholqa.pdf other relevant statistics What is the recommended What are the dangers of • Alcohol is the second largest cause of weekly consumption limit for drinking too much? drug-related deaths and hospitalisations in Australia (after tobacco) (AIHW, men and women? Alcohol is known to be a major cause of 2005a); the following ailments and conditions: The Australian government National Health • Alcohol is the main cause of deaths on and Medical Research Council’s 2009 • Vitamin deficiency and malnutrition; Australian roads. In 1998, over 2000 guidelines advise both men and women • Skin and facial problems; deaths of the total 7000 deaths of to drink no more than two standard drinks • Sexually transmitted infections; persons under 65 years were related to per day to reduce their health risks over a • Female or male sexual dysfunction; alcohol (Ridolfo and Stevenson, 1998); lifetime. The previous guidelines set out • Liver disease/cirrhosis; • In 2004, the age standardised rate were four drinks for men and two drinks for for male deaths due to alcoholic liver women per day, on average. • Brain damage/hallucinations/blackouts; • Gastrointestinal diseases/inflammation of disease as the “underlying cause” was the stomach, gastritis and duodenal ulcers; 5.5 per 100,000, compared with 1.5 per 100,000 for females (ABS 2006b); and • Cardiovascular diseases; • In 2004, the age standardised rate for • Dementia/memory loss; male deaths with mental and behavioural • Infertility/impotence and small genitals; disorders due to alcohol as the • Anaemia/hypertension and impaired underlying cause was 1.9 per 100,000, blood clotting; compared with 0.4 per 100,000 for • Anxiety; females (ABS 2006b); • Stress; These above-mentioned statistics illustrate • Depression; that excessive alcohol consumption can • Cancers of the mouth, oesophagus, seriously damage your health, your personal larynx, liver, breast and rectum; life and the lives of those around you. • Stroke; Source: Australian Bureau of Statistics 2006b, • Suicide; Causes of Death, Australia, 2004, cat.no. 3303.0, • Metabolic syndrome; ABS, Canberra. • Trembling hands and loss of sensation in fingers; • In pregnant women, drinking can potentially lead to foetal alcohol syndrome, characterised by varying degrees of lifelong brain and nerve damage and facial deformity in the baby. Page 2 Health & Wellbeing – Drugs and Alcohol What is the relationship between alcohol and depression? Those affected directly or indirectly by Alcohol is a known depressant, meaning depression know only too well how that it slows down the body in all ways. What is denial and how crippling the illness can be. It is an all- The feelings of relaxation and wellbeing it common is denial? engulfing, frightening mental disease that promotes are due to this general slowing can destroy all sense of control, purpose down and “depressing” of the body’s Denial is present in nearly all and hope. It frequently kills in the form of systems, in particular the brain. Most who have problems with alcohol, suicide. The main symptoms of depression cognitive processes, from reaction time to and is a primitive psychological include sleep problems, fear of social emotional responses, will be dulled. defence mechanism by which the person subconsciously rejects the situations, inability to relax, incessant In individuals who were not depressed implications of an event or situation. dwelling on problems, severe anxiety and when they began drinking, alcohol can Those affected by excessive alcohol desperate black moods. Many alcoholics cause depression. Consumption of consumption will unconsciously will admit that they suffer from depression, alcohol causes an increase in dopamine perform often enormous feats but are unaware that it is related to levels in the brain, leading to feelings of of distorted perception and logic alcohol. pleasure. With this artificially increased to shield them from the truth of destruction. Many alcoholics will admit that they suffer from depression, In addition, admitting that alcohol is but are unaware that it is related to alcohol. the cause of their difficulties means that they must accept the guilt, In all its glory, alcohol appears to be a supply of dopamine, however, the brain shame and disgrace their drinking miracle drug. It can aid sleep, create compensates by producing less. When may have caused, and admit that a sense of social competence and consistently stimulated into reducing problems they have encountered – ease friendly conversation. It promotes dopamine by excessive alcohol intake, the such as marriage breakdown, losing relaxation, causes problems to be brain may cease producing dopamine in a job or losing their driving licence, forgotten momentarily and raises mood. response to other stimuli altogether. The were, in fact, their own fault. This is It works instantly and does not require a result is that the addict now requires the an enormous thing to have to admit prescription. Finally, it is affordable and is drug just to feel “normal” and finds no and take some degree of liability for. even tasty and palatable for most people. pleasure in anything except alcohol. A person suffering from alcohol Like all drugs, however, alcohol has its Understandably an alcoholic lifestyle may dependence may be in denial side effects. First, it can be dangerously lead to depression for other reasons. and when challenged about their addictive. Depression sufferers, with their There is a pattern of loss to the alcoholic’s drinking may typically become very poor sense of self are unlikely to care life that can be inevitable unless help is defensive, irritated, annoyed and about this addiction, or to be able to do sought. Typically, the affected person sometimes even violent. It is for this anything about it should they sense that may potentially lose their job, standing reason that one must tread lightly, they are becoming dependent. in society, driving licence, family, home, not come across as judgmental and health and dignity.
Load more

Recommended publications
  • Drug & Alcohol Testing Program
    Pottawattmie County Drug & Alcohol Testing Program Appendix A Table of Contents POLICY STATEMENT ...................................................................................................................................... 3 SCOPE ............................................................................................................................................................ 4 EDUCATION AND TRAINING .......................................................................................................................... 4 DESIGNATED EMPLOYER REPRESENTATIVE (DER): ....................................................................................... 5 DUTY TO COOPERATE ................................................................................................................................... 5 EMPLOYEE ADMISSION OF ALCOHOL AND CONTROLLED SUBSTANCE USE: (49 CFR Part 382.121) ... 6 PROHIBITED DRUGS AND ILLEGALLY USED CONTROLLED SUBSTANCES: ..................................................... 7 PROHIBITED BEHAVIOR AND CONDUCT: ...................................................................................................... 8 DRUG & ALCOHOL TESTING REQUIREMENTS (49 CFR, Part 40 & 382) ............................................... 10 DRUG & ALCOHOL TESTING CIRCUMSTANCES (49 CFR Part 40 & 382) .............................................. 12 A. Pre-Employment Testing: .................................................................................................... 12 B. Reasonable Suspicion Testing: .........................................................................................
    [Show full text]
  • Guidelines for the Forensic Analysis of Drugs Facilitating Sexual Assault and Other Criminal Acts
    Vienna International Centre, PO Box 500, 1400 Vienna, Austria Tel.: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts United Nations publication Printed in Austria ST/NAR/45 *1186331*V.11-86331—December 2011 —300 Photo credits: UNODC Photo Library, iStock.com/Abel Mitja Varela Laboratory and Scientific Section UNITED NATIONS OFFICE ON DRUGS AND CRIME Vienna Guidelines for the forensic analysis of drugs facilitating sexual assault and other criminal acts UNITED NATIONS New York, 2011 ST/NAR/45 © United Nations, December 2011. All rights reserved. The designations employed and the presentation of material in this publication do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any country, territory, city or area, or of its authorities, or concerning the delimitation of its frontiers or boundaries. This publication has not been formally edited. Publishing production: English, Publishing and Library Section, United Nations Office at Vienna. List of abbreviations . v Acknowledgements .......................................... vii 1. Introduction............................................. 1 1.1. Background ........................................ 1 1.2. Purpose and scope of the manual ...................... 2 2. Investigative and analytical challenges ....................... 5 3 Evidence collection ...................................... 9 3.1. Evidence collection kits .............................. 9 3.2. Sample transfer and storage........................... 10 3.3. Biological samples and sampling ...................... 11 3.4. Other samples ...................................... 12 4. Analytical considerations .................................. 13 4.1. Substances encountered in DFSA and other DFC cases .... 13 4.2. Procedures and analytical strategy...................... 14 4.3. Analytical methodology .............................. 15 4.4.
    [Show full text]
  • Withdrawing Benzodiazepines in Primary Care
    PC\/ICU/ ADTiriC • CNS Drugs 2009,-23(1): 19-34 KtVltW MKIIWLC 1172-7047/I»/O(X)1«119/S4W5/C1 © 2009 Adis Dato Intocmation BV. All rights reserved. Withdrawing Benzodiazepines in Primary Care Malcolm Luder} Andre Tylee^ and ]ohn Donoghue^ 1 Institute of Psychiatry, King's College London, London, England 2 John Moores University, Liverpool, Scotland Contents Abstract ' 19 1. Benzodiazepine Usage 22 2. Interventions 23 2.1 Simple interventions 23 2.2 Piiarmacoiogicai interventions 25 2.3 Psychoiogical Interventions 26 2.4 Meta-Anaiysis ot Various interventions 27 3. Outcomes 28 4. Practicai Issues 29 5. Otiier Medications 30 5.1 Antidepressants 30 5.2 Symptomatic Treatments 30 6. Conciusions 31 Abstract The use of benzodiazepine anxiolytics and hypnotics continues to excite controversy. Views differ from expert to expert and from country to country as to the extent of the problem, or even whether long-term benzodiazepine use actually constitutes a problem. The adverse effects of these drugs have been extensively documented and their effectiveness is being increasingly questioned. Discontinua- tion is usually beneficial as it is followed by improved psychomotor and cognitive functioning, particularly in the elderly. The potential for dependence and addic- tion have also become more apparent. The licensing of SSRIs for anxiety disorders has widened the prescdbers' therapeutic choices (although this group of medications also have their own adverse effects). Melatonin agonists show promise in some forms of insomnia. Accordingly, it is now even more imperative that long-term benzodiazepine users be reviewed with respect to possible discon- tinuation. Strategies for discontinuation start with primary-care practitioners, who are still the main prescdbers.
    [Show full text]
  • 124.210 Schedule IV — Substances Included. 1
    1 CONTROLLED SUBSTANCES, §124.210 124.210 Schedule IV — substances included. 1. Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. 2. Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below: a. Not more than one milligram of difenoxin and not less than twenty-five micrograms of atropine sulfate per dosage unit. b. Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2- propionoxybutane). c. 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol). 3. Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation: a. Alprazolam. b. Barbital. c. Bromazepam. d. Camazepam. e. Carisoprodol. f. Chloral betaine. g. Chloral hydrate. h. Chlordiazepoxide. i. Clobazam. j. Clonazepam. k. Clorazepate. l. Clotiazepam. m. Cloxazolam. n. Delorazepam. o. Diazepam. p. Dichloralphenazone. q. Estazolam. r. Ethchlorvynol. s. Ethinamate. t. Ethyl Loflazepate. u. Fludiazepam. v. Flunitrazepam. w. Flurazepam. x. Halazepam. y. Haloxazolam. z. Ketazolam. aa. Loprazolam. ab. Lorazepam. ac. Lormetazepam. ad. Mebutamate. ae. Medazepam. af. Meprobamate. ag. Methohexital. ah. Methylphenobarbital (mephobarbital).
    [Show full text]
  • S1 Table. List of Medications Analyzed in Present Study Drug
    S1 Table. List of medications analyzed in present study Drug class Drugs Propofol, ketamine, etomidate, Barbiturate (1) (thiopental) Benzodiazepines (28) (midazolam, lorazepam, clonazepam, diazepam, chlordiazepoxide, oxazepam, potassium Sedatives clorazepate, bromazepam, clobazam, alprazolam, pinazepam, (32 drugs) nordazepam, fludiazepam, ethyl loflazepate, etizolam, clotiazepam, tofisopam, flurazepam, flunitrazepam, estazolam, triazolam, lormetazepam, temazepam, brotizolam, quazepam, loprazolam, zopiclone, zolpidem) Fentanyl, alfentanil, sufentanil, remifentanil, morphine, Opioid analgesics hydromorphone, nicomorphine, oxycodone, tramadol, (10 drugs) pethidine Acetaminophen, Non-steroidal anti-inflammatory drugs (36) (celecoxib, polmacoxib, etoricoxib, nimesulide, aceclofenac, acemetacin, amfenac, cinnoxicam, dexibuprofen, diclofenac, emorfazone, Non-opioid analgesics etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, (44 drugs) ketoprofen, ketorolac, lornoxicam, loxoprofen, mefenamiate, meloxicam, nabumetone, naproxen, oxaprozin, piroxicam, pranoprofen, proglumetacin, sulindac, talniflumate, tenoxicam, tiaprofenic acid, zaltoprofen, morniflumate, pelubiprofen, indomethacin), Anticonvulsants (7) (gabapentin, pregabalin, lamotrigine, levetiracetam, carbamazepine, valproic acid, lacosamide) Vecuronium, rocuronium bromide, cisatracurium, atracurium, Neuromuscular hexafluronium, pipecuronium bromide, doxacurium chloride, blocking agents fazadinium bromide, mivacurium chloride, (12 drugs) pancuronium, gallamine, succinylcholine
    [Show full text]
  • Calculating Equivalent Doses of Oral Benzodiazepines
    Calculating equivalent doses of oral benzodiazepines Background Benzodiazepines are the most commonly used anxiolytics and hypnotics (1). There are major differences in potency between different benzodiazepines and this difference in potency is important when switching from one benzodiazepine to another (2). Benzodiazepines also differ markedly in the speed in which they are metabolised and eliminated. With repeated daily dosing accumulation occurs and high concentrations can build up in the body (mainly in fatty tissues) (2). The degree of sedation that they induce also varies, making it difficult to determine exact equivalents (3). Answer Advice on benzodiazepine conversion NB: Before using Table 1, read the notes below and the Limitations statement at the end of this document. Switching benzodiazepines may be advantageous for a variety of reasons, e.g. to a drug with a different half-life pre-discontinuation (4) or in the event of non-availability of a specific benzodiazepine. With relatively short-acting benzodiazepines such as alprazolam and lorazepam, it is not possible to achieve a smooth decline in blood and tissue concentrations during benzodiazepine withdrawal. These drugs are eliminated fairly rapidly with the result that concentrations fluctuate with peaks and troughs between each dose. It is necessary to take the tablets several times a day and many people experience a "mini-withdrawal", sometimes a craving, between each dose. For people withdrawing from these potent, short-acting drugs it has been advised that they switch to an equivalent dose of a benzodiazepine with a long half life such as diazepam (5). Diazepam is available as 2mg tablets which can be halved to give 1mg doses.
    [Show full text]
  • Benzodiazepines Factsheet
    Benzodiazepines This factsheet gives information about benzodiazepine medication. This medication is sometimes used to treat anxiety. Your doctor may prescribe this medication if your anxiety has become severe or if you are very distressed. Benzodiazepines are a type of medication that are used to treat anxiety. You may get side effects from taking this kind of medication. If you get side effects that you are worried about, you should see your doctor. You can become addicted to benzodiazepines. Therefore, you should not take them for longer than one month. You may get withdrawal symptoms when you stop taking benzodiazepines. You should talk to your doctor before you stop taking them. Your doctor may gradually take you off your medication if you have been taking them for a long time. This factsheet covers: 1. What are benzodiazepines? 2. Are there different types of benzodiazepines? 3. Are there any side effects? 4. What if I want to I stop taking benzodiazepines? 5. Do benzodiazepines affect other medication? 6. Does alcohol affect my benzodiazepines? 7. Can I drive when taking benzodiazepines? 8. What else should I consider before taking benzodiazepines? 1 1. What are benzodiazepines? Your doctor may offer you benzodiazepines if you have symptoms of anxiety which are causing you a lot of distress or if you are having difficulty sleeping. Benzodiazepines are a type of sedative and are mostly used as short-term treatment. They work by making the calming chemicals released by your body more powerful. You should not take benzodiazepines for longer than one month. If you take them for longer, you can become tolerant to them (meaning you need more to have the same effect), and you may also become dependent (addicted) to them.
    [Show full text]
  • ATIVAN (Lorazepam) Injection, USP)
    ATIVAN (lorazepam) injection, USP) For intravenous and intramuscular use NOT FOR USE IN NEONATES CONTAINS BENZYL ALCOHOL WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Monitor patients for respiratory depression and sedation (see WARNINGS and PRECAUTIONS, Drug Interactions). DESCRIPTION Lorazepam, a benzodiazepine with antianxiety, sedative, and anticonvulsant effects, is intended for the intramuscular or intravenous routes of administration. It has the chemical formula: 7-chloro-5(2­ chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1, 4-benzodiazepin-2-one. The molecular weight is 321.16, and the C.A.S. No. is [846-49-1]. The structural formula is: Lorazepam is a nearly white powder almost insoluble in water. Each mL of sterile injection contains either 2.0 or 4.0 mg of lorazepam, 0.18 mL polyethylene glycol 400 in propylene glycol with 2.0% benzyl alcohol as preservative. CLINICAL PHARMACOLOGY Lorazepam interacts with the γ-aminobutyric acid (GABA)-benzodiazepine receptor complex, which is widespread in the brain of humans as well as other species. This interaction is presumed to be responsible for lorazepam’s mechanism of action. Lorazepam exhibits relatively high and specific affinity for its recognition site but does not displace GABA. Attachment to the specific binding site enhances the affinity of GABA for its receptor site on the same receptor complex. The pharmacodynamic consequences of benzodiazepine agonist actions include antianxiety effects, sedation, and reduction of seizure activity. The intensity of action is directly related to the degree of benzodiazepine receptor occupancy.
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • 1601 Gilhooly.Qxd
    Brief reports What happens when doctors stop prescribing temazepam? Use of alternative therapies THOMAS C GILHOOLY was followed up by the research nurse (MW) and invited to take part in a home interview. MARY G O WEBSTER NORMAN W POOLE Results Ninety-one patients were recruited: 46 were allocated to the anti- SUE ROSS histamine/chloral group, 45 to the benzodiazepine group. The characteristics of the study groups were similar at the time of SUMMARY recruitment (Table 1). A similar number of patients in each We investigated the withdrawal of temazepam in a single gen- group were interviewed: 36 (78%) of the antihistamine/chloral eral practice using two alternative prescribing policies: an alter- group, 38 (84%) of the benzodiazepine group. native benzodiazepine; or an alternative group of drugs recom- Of the antihistamine/chloral group, 32 (70%) were initially mended for short-term management of insomnia, including changed to one of the recommended antihistamines; 28 (62%) of sedative antihistamines and chloral hydrate. The study showed the benzodiazepine group were prescribed one of the recommend- that temazepam prescribing in general practice can be reduced ed benzodiazepines. Only eight out of 36 (22%) of the antihista- or stopped by using a simple intervention. An alternative benzo- mine/chloral group interviewed were satisfied with the initial diazepine is useful in helping patients to stop their use of hyp- change, compared with 21 out of 38 (55%) of the benzodiazepine notic agents. The use of antihistamines as substitute hypnotics group (χ2 = 8.47; df = 1; P = 0.004). The antihistamine/chloral is not advocated on the basis of our findings.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Drug/Substance Trade Name(S)
    A B C D E F G H I J K 1 Drug/Substance Trade Name(s) Drug Class Existing Penalty Class Special Notation T1:Doping/Endangerment Level T2: Mismanagement Level Comments Methylenedioxypyrovalerone is a stimulant of the cathinone class which acts as a 3,4-methylenedioxypyprovaleroneMDPV, “bath salts” norepinephrine-dopamine reuptake inhibitor. It was first developed in the 1960s by a team at 1 A Yes A A 2 Boehringer Ingelheim. No 3 Alfentanil Alfenta Narcotic used to control pain and keep patients asleep during surgery. 1 A Yes A No A Aminoxafen, Aminorex is a weight loss stimulant drug. It was withdrawn from the market after it was found Aminorex Aminoxaphen, Apiquel, to cause pulmonary hypertension. 1 A Yes A A 4 McN-742, Menocil No Amphetamine is a potent central nervous system stimulant that is used in the treatment of Amphetamine Speed, Upper 1 A Yes A A 5 attention deficit hyperactivity disorder, narcolepsy, and obesity. No Anileridine is a synthetic analgesic drug and is a member of the piperidine class of analgesic Anileridine Leritine 1 A Yes A A 6 agents developed by Merck & Co. in the 1950s. No Dopamine promoter used to treat loss of muscle movement control caused by Parkinson's Apomorphine Apokyn, Ixense 1 A Yes A A 7 disease. No Recreational drug with euphoriant and stimulant properties. The effects produced by BZP are comparable to those produced by amphetamine. It is often claimed that BZP was originally Benzylpiperazine BZP 1 A Yes A A synthesized as a potential antihelminthic (anti-parasitic) agent for use in farm animals.
    [Show full text]